France Lung Cancer Therapeutics Market Report 2022 to 2030

France Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the France Lung Cancer Therapeutics Market will reach a value of $1420 Mn from $820 Mn in 2022, growing at a CAGR of 7.1% during 2022-2030. The Lung Cancer Therapeutics Market in France is dominated by a few domestic pharmaceutical companies such as Sanofi, Ipsen, and Innate Pharma. The Lung Cancer Therapeutics Market in France is segmented into different types of cancer and different therapy type. Some of the major factors affecting the France lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10FRPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Dr. Vishwa Modhia

Buy Now

France Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the France Lung Cancer Therapeutics market will reach a value of $1420 Mn from $820 Mn in 2022, growing at a CAGR of 7.1% during 2022-2030.

France is a developed country in Western Europe with various overseas territories and islands on other continents and in the Indian, Pacific, and Atlantic oceans. In mainland France, 46,363 new cases of lung cancer were reported in 2018, with men accounting for 67% of the occurrences. Lung cancer is the second most prevalent cancer in males and the third most common cancer in women. In France, around 14,500 patients with lung cancer are treated with irradiation each year. At the end of 2018, 169 radiation centres were permitted to operate. Currently, the majority of treatment (about 84 %) is performed utilising conformational approaches with intensity modulation (nearly 95 %), and around 50 % of centres have radiation equipment for intracranial or extracranial stereotactic treatments.

The reasonably effective public health system in France provides for the relatively rapid application of treatment developments in the care of lung cancer patients. According to the latest WHO data published in 2020 Lung Cancers Deaths in France reached 35,657 or 7.46% of total deaths. The age-adjusted Death Rate is 27.51 per 100,000 of the population ranks France 19^th in the world. France's government spends 12.2 % of its GDP on healthcare.

France Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Since 2009, the National Professional Council in Thoracic and Cardiovascular Surgery has served as the sole representative of the surgical speciality for lung cancer trustee authorities in France. The French Society of Thoracic and Cardiovascular Surgery established the EPITHOR national general thoracic surgery database in 2003 with the primary goal of allowing the evaluation of surgical practises at the surgeon, centre, and national levels. EPITHOR recorded 31,381 individuals with primary lung cancer from January 2016 to June 2020. France has a skilled and productive workforce, as well as a changing demographic. Patients in France benefit from an efficient system of access to novel pharmaceuticals through Temporary Use Authorization (TUA). These aspects could boost France's Lung Cancer Therapeutics market.

Market Restraints

In France, lung cancer is a major cause of illness, mortality, and socioeconomic costs. The first-line treatment of ALK and EGFR wildtype metastatic NSCLC has changed rapidly in recent years. The French national agency approved just a pembrolizumab single-drug regimen in August 2018, and a combination of chemotherapy and pembrolizumab was approved in 2020. Despite efforts to offer equitable access to care, certain shadows remain. These factors may deter new entrants into the France Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Sanofi: Sanofi is a French multinational pharmaceutical company that produces several drugs for the treatment of lung cancer, including Taxotere and Jevtana
Ipsen: Ipsen is a French multinational pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
Servier: Servier is a French multinational pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
Innate Pharma: Innate Pharma is a French biotechnology company that is focused on the development of immunotherapies for the treatment of cancer, including lung cancer
Transgene: Transgene is a French biotechnology company that is focused on the development of targeted immunotherapies for the treatment of cancer, including lung cancer

Recent Notable Updates

September 2022: Roche demonstrated at the European Society of Medical Oncology meeting 2022 that Tecentriq monotherapy can outlive chemotherapy in patients with newly diagnosed non-small cell lung cancer who cannot take platinum-based chemotherapy. Merck's Keytruda has long been considered the gold standard of therapy for newly diagnosed non-small cell lung cancer (NSCLC). However, Roche now intends to create a market for Tecentriq by focusing on a hitherto underserved subset of patients.

Healthcare Policies and Reimbursement Scenarios

Several agencies, notably the French National Agency for Medicines and Health Products Safety (ANSM), the National Authority for Health (HAS), and the French healthcare system, regulate and reimburse lung cancer therapies in France. In France, the ANSM is in charge of the regulation and approval of lung cancer medicines. The HAS assesses the cost-effectiveness of lung cancer therapies and recommends whether they should be funded by the French healthcare system. Universal health protection (Protection Universelle Maladie) was established in 2016 as a French social benefit, enabling any person regularly resident in France who is not already covered by another compulsory health insurance plan access to care, reimbursement of care, rewards, and drugs.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.